SEARCH

SEARCH BY CITATION

References

  • 1
    Kumar B, Saraswat A, Kaur I. Palmoplantar lesions in psoriasis: a study of 3065 patients. Acta Derm Venereol 2002; 82: 192195.
  • 2
    Jiaravuthisan MM, Sasseville D, Vender RB et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007; 57: 127.
  • 3
    Menter A, Gottlieb A, Feldman SR et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826850.
  • 4
    Farley E, Masrour S, McKey J, Menter A. Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol 2009; 60: 10241031.
  • 5
    Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med 1995; 332: 581588.
  • 6
    Pettey AA, Balkrishnan R, Rapp SR et al. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol 2003; 49: 271275.
  • 7
    Langley RG, Saurat JH, Reich K. on behalf of the Nail Psoriasis Delphi Expert P. Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus. J Eur Acad Dermatol Venereol 2012; 26: 373381.
  • 8
    Gregoriou S, Kalogeromitros D, Kosionis N et al. Treatment options for nail psoriasis. Expert Rev Dermatol 2008; 3: 339344.
  • 9
    Adışen E, Tekin O, Gülekon A, Gürer MA. A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients. J Eur Acad Dermatol Venereol 2009; 23: 814819.
  • 10
    Frankel AJ, Goldenberg G. Insights into treating palmoplantar psoriasis. Skin and Aging 2010; 18: 3237.
  • 11
    Handa S. Newer trends in the management of psoriasis at difficult to treat locations: scalp, palmoplantar disease and nails. Indian J Dermatol Venereol Leprol 2010; 76: 634644.
  • 12
    Frankel AJ, Goldenberg G. Assessing the risks & benefits of biologic therapies for psoriasis. Skin and Aging 2011; 19: 2430.
  • 13
    Weinberg JM. Successful treatment of recalcitrant palmoplantar psoriasis with etanercept. Cutis 2003; 72: 396398.
  • 14
    Di Lernia V, Guareschi E. Successful treatment of hand and foot psoriasis with infliximab. Dermatol Online J 2010; 16: 8.
  • 15
    Bissonnette R, Poulin Y, Guenther L et al. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study. J Eur Acad Dermatol Venereol 2011; 25: 14021408.
  • 16
    Bulai Livideanu C, Lahfa M, Mazereeuw-Hautier J, Paul C. Efficacy of ustekinumab in palmoplantar psoriasis. Dermatol 2010; 221: 321323.
  • 17
    Au SC, Goldminz AM, Kim N et al. Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate to severe palmoplantar psoriasis. J Dermatolog Treat 2012; 24: 179187.
  • 18
    Prossick TA, Belsito DV. Alefacept in the treatment of recalcitrant palmoplantar and erythrodermic psoriasis. Cutis 2006; 78: 178180.
  • 19
    Lior S, Grigory K, Pnina S et al. Therapeutic Hotline: alefacept in the treatment of hyperkeratotic palmoplantar psoriasis. Dermatol Ther 2010; 23: 556560.
  • 20
    Myers W, Christiansen L, Gottlieb AB. Treatment of palmoplantar psoriasis with intramuscular alefacept. J Am Acad Dermatol 2005; 53: S127S129.
  • 21
    Takahashi MD, Chouela EN, Dorantes GL et al. Efalizumab in the Treatment of Scalp, Palmoplantar and Nail Psoriasis: results of a 24-Week Latin American Study. Arch Drug Inf 2010; 3: 18.
  • 22
    Cohen DJ, Scherschun L. Case reports: Practical experience with efalizumab in hand and foot psoriasis. J Drugs Dermatol 2007; 6: 12241230.
  • 23
    Saurat JH, Stingl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558566.
  • 24
    Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106115.
  • 25
    Leonardi C, Langley RG, Papp K et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol 2011; 147: 429436.
  • 26
    Menter A, Gordon KB, Leonardi CL et al. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol 2010; 63: 448456.
  • 27
    Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol 2008; 58: 443446.
  • 28
    Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999; 141: 185191.
    Direct Link:
  • 29
    Fabroni C, Gori A, Troiano M et al. Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients. J Eur Acad Dermatol Venereol 2011; 25: 549553.
  • 30
    Kyriakou A, Patsatsi A, Sotiriadis D. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study. J Dermatolog Treat 2013; 24: 162168.
  • 31
    Rigopoulos D, Gregoriou S, Makris M, Ioannides D. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study. Dermatology 2011; 223: 325329.
  • 32
    Rigopoulos D, Gregoriou S, Lazaridou E et al. Treatment of nail psoriasis with adalimumab: an open label unblinded study. J Eur Acad Dermatol Venereol 2010; 24: 530534.
  • 33
    Van den Bosch F, Manger B, Goupille P et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 2010; 69: 394399.
  • 34
    Sánchez-Regaña M, Sola-Ortigosa J, Alsina-Gibert M et al. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy). J Eur Acad Dermatol Venereol 2011; 25: 579586.
  • 35
    Patsatsi A, Kyriakou A, Sotiriadis D. Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study. J Dermatolog Treat 2013; 24: 96100.
  • 36
    Saraceno R, Bianchi L, Peietroleonardo L et al. Remission and time of resolution of nail psoriasis: a comparison amoung antitumour necrosis factor-alpha inhibitors. Br J Dermatol 2008; 159(1418): P1447.
  • 37
    Zangrilli A, Talamonti M, Saraceno R, Chimenti S. Clinical severity instruments. In: Chimenti S, ed. Psoriasis. Florence, Italy: Societa Editrice Italiana, 2005: pp.113119.
  • 38
    Bhushan M, Burden AD, McElhone K et al. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2001; 145: 546553.
  • 39
    Brunasso AM, Salvini C, Massone C. Efalizumab for severe palmo-plantar psoriasis: an open-label pilot trial in five patients. J Eur Acad Dermatol Venereol 2009; 23: 415419.